Alamar Biosciences, INC

Alamar Biosciences, Inc. has appointed Robert Ragusa to its Board of Directors, effective September 1, 2026, strengthening its governance structure.

Alamar Biosciences announced the passing of board member Ian Ratcliffe and subsequent adjustments to its board size and committee appointments.

John L. Brottem, General Counsel of Alamar Biosciences, Inc., reported multiple transactions in common stock on September 14, 2026.

Sands Capital Life Sciences Pulse Fund II, L.P. reports a 6.1% stake in Alamar Biosciences, Inc. following the passing of board member Ian Ratcliffe.

Yuling Luo has reported beneficial ownership of 6.4% of Alamar Biosciences' common stock as of June 30, 2026, including exercisable options and shares held by spouse.

Several Qiming entities have entered into a joint filing agreement to collectively report their beneficial ownership of Alamar Biosciences, Inc. common stock.

Sherpa Healthcare Fund II, L.P. and Sherpa Healthcare Co-Investment Fund, L.P., along with Daqing Cai, have reported beneficial ownership of 7.2% of Alamar Biosciences, Inc. common stock.